Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi
Patients with lab abnormalities saw significantly lower TTD and OS than those without abnormalities. Patients with liver abnormalities saw significantly shorter TTD and OS across all treatments likely driving this association. More real-world studies of patients with lab abnormalities are needed to empower oncologists when making treatment decisions in high-risk populations, to discuss prognosis and to inform RCT eligibility criteria.
Authors
- Kelly Kenzik (ORCID: https://orcid.org/0000-0002-6402-8446)
- Andrés Azuero (ORCID: https://orcid.org/0000-0001-9883-1424)
- Mackenzie Elisha Fowler (ORCID: https://orcid.org/0000-0003-2952-3705)
- Jeffrey Franks (ORCID: https://orcid.org/0000-0001-9076-9072)
- Russell Lee Griffin (ORCID: https://orcid.org/0000-0002-5004-7996)
- Nusrat Jahan (ORCID: https://orcid.org/0000-0001-8700-2209)
- Gabrielle Betty Rocque (ORCID: https://orcid.org/0000-0003-4188-9785)
Institutions
- Boston Medical Center (US)
- University of Alabama at Birmingham (US)
- O'Neal Comprehensive Cancer Center
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1007/s10549-025-07751-1
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52